NCT06355258View on ClinicalTrials.gov

A Study of the Efficacy of Troxerutin in Preventing Thrombotic Events in COVID-19 Patients

PHASE1RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

December 15, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

March 31, 2025

Conditions
COVID 19 Associated Coagulopathy
Interventions
DRUG

Troxerutin

Oral troxerutin tablets, with a dosage of 3 tablets (60 mg/tablet) orally, twice daily

DRUG

Placebo

Oral placebo tablets, with a dosage of 3 tablets (60 mg/tablet) orally, twice daily

DRUG

placebo + low molecular weight heparin

2000 IU LMWH once a day + Oral placebo tablets, with a dosage of 3 tablets (60 mg/tablet) orally, twice daily

DRUG

troxerutin + low molecular weight heparin

2000 IU LMWH once a day + Oral troxerutin tablets, with a dosage of 3 tablets (60 mg/tablet) orally, twice daily

Trial Locations (1)

Unknown

RECRUITING

Shaoxing central hospital, Shaoxing

All Listed Sponsors
collaborator

Shaoxing Central Hospital

OTHER

collaborator

Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University

UNKNOWN

lead

Westlake University

OTHER